Wir nutzen Cookies auf unserer Website. Einige von ihnen sind essenziell, während andere uns helfen, diese Website und Ihre Erfahrung zu verbessern.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Speichert die aktuelle PHP-Session.
Retention period: Dieses Cookie bleibt nur für die aktuelle Browsersitzung bestehen.
Inhalte von Drittanbietern, bspw. Aktienwidgets, werden standardmäßig blockiert. Wenn Cookies von Drittanbietern akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Einwilligung mehr.
Wir verwenden zur Aktien-Chart-Anzeige den Anbieter TradingView. Dieser setzt weitere Cookies zur Analyse seiner Dienste ein.
Sie können unseren Newsletter abonnieren, dazu nutzen wir die Dienste von EQS. Dieser Anbieter setzt bei der Registrierung selbst verschiedene Cookies zur Nutzungsanalyse seiner Dienste ein.
In its meeting today, the Supervisory Board of HAEMATO AG appointed Mr. Attila Strauss to the Executive Board of HAEMATO AG with effect from 01.04.2022. Mr. Attila Strauss has already been working as Chief Operating Officer at HAEMATO PHARM GmbH since 01.05.2021 and has also been Managing Director of the company since 01.10.2021.
HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its medical device portfolio in the fight against Corona virus. In addition to the already introduced Point-of-Care (PoC) PCR device, HAEMATO is now also marketing the Mini Dock, an alternative PoC device that sets a benchmark in terms of price.
With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with regards to the new quarantine regulations.
In operational terms, HAEMATO AG is heading for a record year following the acquisition of M1 Aesthetics GmbH. In addition, the expansion of their private label business is increasingly coming into focus. In this regard, the company plans to expand its portfolio with a botulinum toxin product under its own brand. GBC analyst Cosmin Filker spoke …
HAEMATO continues to grow: consolidated revenue in the third quarter of 2021 increased by 9% year-over-year to EUR 65.1 million. From 1 January to 30 September 2021, consolidated revenue rose to 216.6 million euros. This corresponds to a growth of 23 % compared to the same period of the previous year. Group EBIT increased to 1.4 million euros in …
Seoul and Schönefeld, 25th October 2021 - HAEMATO PHARM GmbH ("HAEMATO"), a wholly owned subsidiary of HAEMATO AG (ISIN: DE000289VV1) is expanding its own portfolio with a botulinum toxin product from the pharmaceutical company Huons BioPharma Co., Ltd. ("Huons BioPharma"), based in Seoul, Korea. For this purpose, Huons BioPharma and HAEMATO have …
Menu
